LanzkronS, LittleJ, FieldJ, . Increased acute care utilization in a prospective cohort of adults with sickle cell disease. Blood Adv2018;2:2412–7.doi:10.1182/bloodadvances.2018018382http://www.ncbi.nlm.nih.gov/pubmed/30254105
AultA. US FDA approves first drug for sickle-cell anaemia. Lancet1998;351:809.doi:10.1016/S0140-6736(05)78941-8
4.
BradfordC, MiodownikH, ThomasM, . Patient-focused inquiry on hydroxyurea therapy adherence and reasons for discontinuation in adults with sickle cell disease. Am J Hematol2022;97:E93–5.doi:10.1002/ajh.26438http://www.ncbi.nlm.nih.gov/pubmed/34914130
5.
LanzkronS, HaywoodC, FaganPJ, . Examining the effectiveness of hydroxyurea in people with sickle cell disease. J Health Care Poor Underserved2010;21:277–86.doi:10.1353/hpu.0.0272http://www.ncbi.nlm.nih.gov/pubmed/20173269
6.
AliMA, AhmadA, ChaudryH, . Efficacy and safety of recently approved drugs for sickle cell disease: a review of clinical trials. Exp Hematol2020;92:11–18.doi:10.1016/j.exphem.2020.08.008http://www.ncbi.nlm.nih.gov/pubmed/32841705
7.
VichinskyE, HoppeCC, AtagaKI, . A phase 3 randomized trial of Voxelotor in sickle cell disease. N Engl J Med2019;381:509–19.doi:10.1056/NEJMoa1903212http://www.ncbi.nlm.nih.gov/pubmed/31199090
8.
HowardJ, AtagaKI, BrownRC, . Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol2021;8:e323–33.doi:10.1016/S2352-3026(21)00059-4
9.
IdowuM, HaqueA, WilliamsEA, . Patient perception of voxelotor treatment benefit in sickle cell disease. J Investig Med2022;70:1316–9.doi:10.1136/jim-2021-002215
10.
CurtisSA, BetancourtJ, KottapalliN, . Voxelotor use in adults with sickle cell disease in a real‐world setting. Am J Hematol2022;97:E125–8.doi:10.1002/ajh.26453
